Donepezil-induced improvement in delayed matching accuracy by young and old rhesus monkeys

Jerry J. Buccafusco, Alvin V Terry

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Donepezil (Aricept®), a long-acting cholinesterase inhibitor, is widely used in the treatment of Alzheimer's disease to improve cognition and memory. Many drugs within the class of cognition-enhancing agents, both currently approved medications and those under development, have clinical indications narrowly relegated to Alzheimer's disease. The purpose of this study was to determine whether the efficacy attributed to donepezil in its ability to improve delayed matching accuracy by monkeys was independent of age. Male and female rhesus monkeys (n = 17) ranging from 9 to 29 yr of age were administered donepezil (10, 25, 50, and 100 μg/kg, im) during 4 discrete test days. Donepezil treatment improved average task accuracy, but intersubject variability prohibited statistical significance. When animals were considered individually, the most effective dose of donepezil was associated with a highly significant increase in group task performance that was consistent with enhanced recall during testing. The variability associated with the dose-response analysis was attributable primarily to subject age, such that older monkeys required higher doses of donepezil. Yet at doses that were effective in all subjects, there was no relationship between age and the improvement in task accuracy. Likewise, there was no association between baseline task proficiency and improvement in task accuracy.

Original languageEnglish (US)
Pages (from-to)85-91
Number of pages7
JournalJournal of Molecular Neuroscience
Volume24
Issue number1
StatePublished - Aug 1 2004

Fingerprint

Macaca mulatta
Cognition
Haplorhini
Alzheimer Disease
Aptitude
Cholinesterase Inhibitors
Task Performance and Analysis
donepezil
Animals
Data storage equipment
Testing
Pharmaceutical Preparations

Keywords

  • Aging
  • Cholinesterase inhibitor
  • Cognition
  • Delayed matching
  • Donepezil
  • Memory
  • Nonhuman primate
  • Recall

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience

Cite this

Donepezil-induced improvement in delayed matching accuracy by young and old rhesus monkeys. / Buccafusco, Jerry J.; Terry, Alvin V.

In: Journal of Molecular Neuroscience, Vol. 24, No. 1, 01.08.2004, p. 85-91.

Research output: Contribution to journalArticle

@article{024d765b03734ad1ad5457669b42369e,
title = "Donepezil-induced improvement in delayed matching accuracy by young and old rhesus monkeys",
abstract = "Donepezil (Aricept{\circledR}), a long-acting cholinesterase inhibitor, is widely used in the treatment of Alzheimer's disease to improve cognition and memory. Many drugs within the class of cognition-enhancing agents, both currently approved medications and those under development, have clinical indications narrowly relegated to Alzheimer's disease. The purpose of this study was to determine whether the efficacy attributed to donepezil in its ability to improve delayed matching accuracy by monkeys was independent of age. Male and female rhesus monkeys (n = 17) ranging from 9 to 29 yr of age were administered donepezil (10, 25, 50, and 100 μg/kg, im) during 4 discrete test days. Donepezil treatment improved average task accuracy, but intersubject variability prohibited statistical significance. When animals were considered individually, the most effective dose of donepezil was associated with a highly significant increase in group task performance that was consistent with enhanced recall during testing. The variability associated with the dose-response analysis was attributable primarily to subject age, such that older monkeys required higher doses of donepezil. Yet at doses that were effective in all subjects, there was no relationship between age and the improvement in task accuracy. Likewise, there was no association between baseline task proficiency and improvement in task accuracy.",
keywords = "Aging, Cholinesterase inhibitor, Cognition, Delayed matching, Donepezil, Memory, Nonhuman primate, Recall",
author = "Buccafusco, {Jerry J.} and Terry, {Alvin V}",
year = "2004",
month = "8",
day = "1",
language = "English (US)",
volume = "24",
pages = "85--91",
journal = "Journal of Molecular Neuroscience",
issn = "0895-8696",
publisher = "Humana Press",
number = "1",

}

TY - JOUR

T1 - Donepezil-induced improvement in delayed matching accuracy by young and old rhesus monkeys

AU - Buccafusco, Jerry J.

AU - Terry, Alvin V

PY - 2004/8/1

Y1 - 2004/8/1

N2 - Donepezil (Aricept®), a long-acting cholinesterase inhibitor, is widely used in the treatment of Alzheimer's disease to improve cognition and memory. Many drugs within the class of cognition-enhancing agents, both currently approved medications and those under development, have clinical indications narrowly relegated to Alzheimer's disease. The purpose of this study was to determine whether the efficacy attributed to donepezil in its ability to improve delayed matching accuracy by monkeys was independent of age. Male and female rhesus monkeys (n = 17) ranging from 9 to 29 yr of age were administered donepezil (10, 25, 50, and 100 μg/kg, im) during 4 discrete test days. Donepezil treatment improved average task accuracy, but intersubject variability prohibited statistical significance. When animals were considered individually, the most effective dose of donepezil was associated with a highly significant increase in group task performance that was consistent with enhanced recall during testing. The variability associated with the dose-response analysis was attributable primarily to subject age, such that older monkeys required higher doses of donepezil. Yet at doses that were effective in all subjects, there was no relationship between age and the improvement in task accuracy. Likewise, there was no association between baseline task proficiency and improvement in task accuracy.

AB - Donepezil (Aricept®), a long-acting cholinesterase inhibitor, is widely used in the treatment of Alzheimer's disease to improve cognition and memory. Many drugs within the class of cognition-enhancing agents, both currently approved medications and those under development, have clinical indications narrowly relegated to Alzheimer's disease. The purpose of this study was to determine whether the efficacy attributed to donepezil in its ability to improve delayed matching accuracy by monkeys was independent of age. Male and female rhesus monkeys (n = 17) ranging from 9 to 29 yr of age were administered donepezil (10, 25, 50, and 100 μg/kg, im) during 4 discrete test days. Donepezil treatment improved average task accuracy, but intersubject variability prohibited statistical significance. When animals were considered individually, the most effective dose of donepezil was associated with a highly significant increase in group task performance that was consistent with enhanced recall during testing. The variability associated with the dose-response analysis was attributable primarily to subject age, such that older monkeys required higher doses of donepezil. Yet at doses that were effective in all subjects, there was no relationship between age and the improvement in task accuracy. Likewise, there was no association between baseline task proficiency and improvement in task accuracy.

KW - Aging

KW - Cholinesterase inhibitor

KW - Cognition

KW - Delayed matching

KW - Donepezil

KW - Memory

KW - Nonhuman primate

KW - Recall

UR - http://www.scopus.com/inward/record.url?scp=16544394141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16544394141&partnerID=8YFLogxK

M3 - Article

C2 - 15314255

AN - SCOPUS:16544394141

VL - 24

SP - 85

EP - 91

JO - Journal of Molecular Neuroscience

JF - Journal of Molecular Neuroscience

SN - 0895-8696

IS - 1

ER -